Type Mutant Stock; Targeted Mutation; Transgenic; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Species laboratory mouse Donating Investigator Robert L Nussbaum, University of California San Francisco Description
These double transgenic homozygous mice (dbl-PAC-Tg(SNCAA30P);Snca-/- mice) are viable and fertile, harboring a Snca knockout allele and two independently inserted transgenes encoding the human A30P-mutant α-synuclein associated with autosomal dominant Parkinson's disease. As homozygotes, expression of endogenous mouse α-synuclein is abolished and replaced by α-synuclein*A30P from the PAC-Tg(SNCAA30P). Because PAC-Tg(SNCAA30P) line 1 inserted on the X chromosome and line 2 inserted on a somatic chromosome, homozygous females have four total insertions and homozygous males have three total insertions. While brain RNA expression of SNCAA30P is more than 10-fold greater compared to normal endogenous mouse α-synuclein, protein levels are only 1 to 1.5-fold greater. In colon however, both RNA and protein expression of SNCAA30P are ~80-fold greater than normal endogenous mouse α-synuclein. By three months of age, dbl-PAC-Tg(SNCAA30P);Snca-/- mice show robust abnormalities in enteric nervous system function (impaired colonic motility [males only] and prolonged gut transit time). No detectable motor behavior impairments, autonomic abnormalities, olfactory dysfunction, dopaminergic deficits, Lewy body inclusions or neurodegeneration are associated with α-synuclein*A30P expression in these double transgenic mice. The very early gastrointestinal dysfunction in the absence of major central nervous system pathology in dbl-PAC-Tg(SNCAA30P);Snca-/- mice mimics what is seen early in human Parkinson's disease, when enteric nervous system dysfunction may precede the more classical motor symptoms by years to decades.Development
To generate the PAC-Tg(SNCAA30P) transgene, the 146 kb RPCI-1 human male P1 artificial chromosome (PAC) clone 27M07, containing the entire human SNCA (synuclein, alpha (non A4 component of amyloid precursor)) gene and 34 kb of its upstream region, was modified to have the A30P human mutation associated with autosomal dominant Parkinson's disease (G>C substitution at base 351 of the cDNA sequence). This transgene was microinjected into the pronuclei of fertilized FVB/N ova. Each transgenic founder mouse was bred to FVB/N wildtype mice to generate the individual founder lines (1 and 2). Each PAC-Tg(SNCAA30P) transgenic line was independently maintained as coisogenic on the FVB/N genetic background by breeding together as homozygotes.To generate the Snca knockout allele, a targeting vector was designed to replace exons 4 and 5 with a reverse-oriented neomycin resistance cassette (PGK-neo from the vector pPNT). The construct was electroporated into 129S6/SvEvTac-derived TC-1 embryonic stem (ES) cells. Correctly targeted ES cells were injected into recipient blastocysts and the resulting mutant mice were generated and maintained as coisogenic on the 129S6/SvEvTac genetic background.
To generate the dbl-PAC-Tg(SNCAA30P);Snca-/- strain, homozygous PAC-Tg(SNCAA30P) line 1 mice (FVB/N genetic background) were bred with mice homozygous for the Snca knockout allele (129S6/SvEvTac genetic background). Similarly, PAC-Tg(SNCAA30P) line 2 homozygotes were bred with Snca knockout mice. These two mutant strains were then intercrossed and bred to homozygosity to create the double transgenic strain. Because PAC-Tg(SNCAA30P) line 1 inserted on the X chromosome and line 2 inserted on a somatic chromosome, homozygous dbl-PAC-Tg(SNCAA30P);Snca-/- females have four total insertions and homozygous males have three total insertions. This double transgenic strain was maintained on a mixed FVB/N;129S6/SvEvTac background using multiple breeding units without repeated brother-sister matings: thus the only portions of the FVB/N or 129S6/SvEvTac genomes fixed in these mice are the FVB/N regions flanking the PAC-Tg(SNCAA30P) transgene insertion sites and the 129S6/SvEvTac regions around the Snca knockout allele. The dbl-PAC-Tg(SNCAA30P);Snca-/- mice were sent to The Jackson Laboratory Repository. Upon arrival, mice were bred together to establish the colony.
| Control | ||
|---|---|---|
| None Available | ||
| Considerations for Choosing Controls | ||
Parkinson's Disease Models
005987 129-Achetm1Loc/J 007587 129S-Park2tm1Rpa/J 002779 129S-Parp1tm1Zqw/J 017001 129S.B6N-Plk2tm1Elan/J 016198 129S6.Cg-Tg(Camk2a-tTA)1Mmay/JlwsJ 004608 B6(Cg)-Htra2mnd2/J 008133 B6.129-Sncbtm1Sud/J 008084 B6.129P2-Drd4tm1Dkg/J 004744 B6.129P2-Esr1tm1Ksk/J 013586 B6.129P2-Gt(ROSA)26Sortm1Nik/J 002609 B6.129P2-Nos2tm1Lau/J 008843 B6.129P2-Sncgtm1Vlb/J 016566 B6.129S-Hcn1tm2Kndl/J 004322 B6.129S1-Mapk10tm1Flv/J 003190 B6.129S2-Drd2tm1Low/J 006582 B6.129S4-Park2tm1Shn/J 017946 B6.129S4-Pink1tm1Shn/J 005934 B6.129S4-Ucp2tm1Lowl/J 004936 B6.129S6(Cg)-Spp1tm1Blh/J 012453 B6.129X1(FVB)-Lrrk2tm1.1Cai/J 017009 B6.129X1-Nfe2l2tm1Ywk/J 009346 B6.Cg-Lrrk2tm1.1Shn/J 005491 B6.Cg-Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J 006577 B6.Cg-Park7tm1Shn/J 000567 B6.Cg-T2J +/+ Qkqk-v/J 007004 B6.Cg-Tg(Camk2a-tTA)1Mmay/DboJ 003139 B6.Cg-Tg(DBHn-lacZ)8Rpk/J 007673 B6.Cg-Tg(Gad1-EGFP)3Gfng/J 012466 B6.Cg-Tg(Lrrk2)6Yue/J 012467 B6.Cg-Tg(Lrrk2*G2019S)2Yue/J 008323 B6.Cg-Tg(Mc4r-MAPT/Sapphire)21Rck/J 008321 B6.Cg-Tg(Npy-MAPT/Sapphire)1Rck/J 008324 B6.Cg-Tg(Pmch-MAPT/CFP)1Rck/J 008322 B6.Cg-Tg(Pomc-MAPT/Topaz)1Rck/J 007894 B6.Cg-Tg(Rgs4-EGFP)4Lvt/J 012588 B6.Cg-Tg(TH-ALPP)1Erav/J 012265 B6.Cg-Tg(THY1-SNCA*A30P)TS2Sud/J 008859 B6.Cg-Tg(THY1-SNCA*A53T)F53Sud/J 008135 B6.Cg-Tg(THY1-SNCA*A53T)M53Sud/J 008601 B6.Cg-Tg(Th-cre)1Tmd/J 013583 B6.Cg-Tg(tetO-LRRK2)C7874Cai/J 000544 B6.D2-Cacna1atg/J 012445 B6.FVB-Tg(LRRK2)WT1Mjfa/J 012446 B6.FVB-Tg(LRRK2*G2019S)1Mjfa/J 006660 B6.SJL-Slc6a3tm1.1(cre)Bkmn/J 008364 B6;129-Chattm1(cre/ERT)Nat/J 009688 B6;129-Dbhtm2(Th)Rpa Thtm1Rpa/J 008883 B6;129-Gt(ROSA)26Sortm1(SNCA*A53T)Djmo/TmdJ 008889 B6;129-Gt(ROSA)26Sortm2(SNCA*119)Djmo/TmdJ 008886 B6;129-Gt(ROSA)26Sortm3(SNCA*E46K)Djmo/TmdJ 009347 B6;129-Lrrk2tm1.1Shn/J 016209 B6;129-Lrrk2tm2.1Shn/J 016210 B6;129-Lrrk2tm3.1Shn/J 013050 B6;129-Pink1tm1Aub/J 004807 B6;129-Psen1tm1Mpm Tg(APPSwe,tauP301L)1Lfa/Mmjax 006390 B6;129-Sncatm1Sud Sncbtm1.1Sud/J 008532 B6;129-Thtm1(cre/Esr1)Nat/J 008333 B6;129P2-Dldtm1Ptl/J 008333 B6;129P2-Dldtm1Ptl/J 002596 B6;129P2-Nos2tm1Lau/J 003243 B6;129S-Tnfrsf1atm1Imx Tnfrsf1btm1Imx/J 003692 B6;129X1-Sncatm1Rosl/J 016575 B6;C3-Tg(PDGFB-LRRK2*G2019S)340Djmo/J 016576 B6;C3-Tg(PDGFB-LRRK2*R1441C)574Djmo/J 008169 B6;C3-Tg(Prnp-MAPT*P301S)PS19Vle/J 004479 B6;C3-Tg(Prnp-SNCA*A53T)83Vle/J 000231 B6;C3Fe a/a-Csf1op/J 012450 B6;D2-Tg(tetO-SNCA)1Cai/J 013725 B6;SJL-Tg(LRRK2)66Mjff/J 016555 B6;SJL-Tg(Nqo1-ALPP)1Jaj/J 008473 B6;SJL-Tg(THY1-SNCA*A30P)M30Sud/J 008134 B6;SJL-Tg(THY1-SNCA*A30P)TS2Sud/J 016976 B6C3-Tg(tetO-SNCA*A53T)33Vle/J 000506 B6C3Fe a/a-Qkqk-v/J 003741 B6D2-Tg(Prnp-MAPT)43Vle/J 018768 B6N.Cg-Tg(SNCA*E46K)3Elan/J 012621 C.129S(B6)-Chrna3tm1.1Hwrt/J 016120 C57BL/6-Lrrk1tm1.1Mjff/J 012444 C57BL/6-Lrrk2tm1Mjfa/J 008389 C57BL/6-Tg(THY1-SNCA)1Sud/J 012769 C57BL/6-Tg(Thy1-Sncg)HvP36Putt/J 005706 C57BL/6-Tg(tetO-CDK5R1/GFP)337Lht/J 006618 C57BL/6-Tg(tetO-COX8A/EYFP)1Ksn/J 008245 C57BL/6J-Tg(Th-SNCA)5Eric/J 008239 C57BL/6J-Tg(Th-SNCA*A30P*A53T)39Eric/J 016122 C57BL/6N-Lrrk1tm1.1Mjff Lrrk2tm1.1Mjff/J 016121 C57BL/6N-Lrrk2tm1.1Mjff/J 016123 C57BL/6N-Sncatm1Mjff/J 016936 C57BL/6N-Tg(Thy1-SNCA)12Mjff/J 017682 C57BL/6N-Tg(Thy1-SNCA)15Mjff/J 007677 CB6-Tg(Gad1-EGFP)G42Zjh/J 009610 FVB/N-Tg(LRRK2)1Cjli/J 009609 FVB/N-Tg(LRRK2*G2019S)1Cjli/J 009604 FVB/N-Tg(LRRK2*R1441G)135Cjli/J 009090 FVB/NJ-Tg(Slc6a3-PARK2*Q311X)AXwy/J 017678 FVB;129-Pink1tm1Aub Tg(Prnp-SNCA*A53T)AAub/J 017744 FVB;129-Tg(Prnp-SNCA*A53T)AAub/J 010710 FVB;129S6-Sncatm1Nbm Tg(SNCA)1Nbm/J 010799 FVB;129S6-Sncatm1Nbm Tg(SNCA*A53T)1Nbm Tg(SNCA*A53T)2Nbm/J 004808 STOCK Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J 000942 STOCK Pitx3ak/2J 014092 STOCK Tg(ACTB-tTA2,-MAPT/lacZ)1Luo/J 006340 STOCK Tg(Gad1-EGFP)98Agmo/J 017000 STOCK Tg(SNCA*E46K)3Elan/J 008474 STOCK Tg(THY1-SNCA*A53T)F53Sud/J 008132 STOCK Tg(THY1-Snca)M1mSud/J 012441 STOCK Tg(tetO-LRRK2*G2019S)E3Cai/J 012442 STOCK Tg(tetO-SNCA*A53T)E2Cai/J 012449 STOCK Tg(teto-LRRK2)C7874Cai/J View Parkinson's Disease Models (109 strains)
Strains carrying Sncatm1Nbm allele
010710 FVB;129S6-Sncatm1Nbm Tg(SNCA)1Nbm/J 010799 FVB;129S6-Sncatm1Nbm Tg(SNCA*A53T)1Nbm Tg(SNCA*A53T)2Nbm/J View Strains carrying Sncatm1Nbm (2 strains)
Strains carrying other alleles of SNCA
006823 B6.Cg-Tg(Prnp-SNCA*A53T)23Mkle/J 008859 B6.Cg-Tg(THY1-SNCA*A53T)F53Sud/J 008135 B6.Cg-Tg(THY1-SNCA*A53T)M53Sud/J 008883 B6;129-Gt(ROSA)26Sortm1(SNCA*A53T)Djmo/TmdJ 008889 B6;129-Gt(ROSA)26Sortm2(SNCA*119)Djmo/TmdJ 008886 B6;129-Gt(ROSA)26Sortm3(SNCA*E46K)Djmo/TmdJ 004479 B6;C3-Tg(Prnp-SNCA*A53T)83Vle/J 012450 B6;D2-Tg(tetO-SNCA)1Cai/J 008473 B6;SJL-Tg(THY1-SNCA*A30P)M30Sud/J 008134 B6;SJL-Tg(THY1-SNCA*A30P)TS2Sud/J 016976 B6C3-Tg(tetO-SNCA*A53T)33Vle/J 018768 B6N.Cg-Tg(SNCA*E46K)3Elan/J 008389 C57BL/6-Tg(THY1-SNCA)1Sud/J 008245 C57BL/6J-Tg(Th-SNCA)5Eric/J 008239 C57BL/6J-Tg(Th-SNCA*A30P*A53T)39Eric/J 016936 C57BL/6N-Tg(Thy1-SNCA)12Mjff/J 017682 C57BL/6N-Tg(Thy1-SNCA)15Mjff/J 017678 FVB;129-Pink1tm1Aub Tg(Prnp-SNCA*A53T)AAub/J 017744 FVB;129-Tg(Prnp-SNCA*A53T)AAub/J 010710 FVB;129S6-Sncatm1Nbm Tg(SNCA)1Nbm/J 010799 FVB;129S6-Sncatm1Nbm Tg(SNCA*A53T)1Nbm Tg(SNCA*A53T)2Nbm/J 017000 STOCK Tg(SNCA*E46K)3Elan/J 008474 STOCK Tg(THY1-SNCA*A53T)F53Sud/J 012442 STOCK Tg(tetO-SNCA*A53T)E2Cai/J View Strains carrying other alleles of SNCA (24 strains)
Strains carrying other alleles of Snca
006390 B6;129-Sncatm1Sud Sncbtm1.1Sud/J 003692 B6;129X1-Sncatm1Rosl/J 016123 C57BL/6N-Sncatm1Mjff/J 008132 STOCK Tg(THY1-Snca)M1mSud/J View Strains carrying other alleles of Snca (4 strains)
Visit the Parkinson's Disease Resource site for helpful information on Parkinson's and research resources.
View Related Disease (OMIM) Terms
Related Disease (OMIM) Terms provided by MGI
- Characteristics of this human disease are associated with transgenes and other mutation types in the mouse.
Parkinson Disease 1, Autosomal Dominant; PARK1
- Potential model based on gene homology relationships. Phenotypic similarity to the human disease has not been tested. Dementia, Lewy Body; DLB (SNCA)
Parkinson Disease 4, Autosomal Dominant; PARK4 (SNCA)
View Mammalian Phenotype Terms
Mammalian Phenotype Terms provided by MGI
assigned by genotype
Sncatm1Nbm/Sncatm1Nbm Tg(SNCA*A30P)1Nbm/Tg(SNCA*A30P)1Nbm Tg(SNCA*A30P)2Nbm/Tg(SNCA*A30P)2Nbm
involves: 129S6/SvEvTac * FVB/N
- digestive/alimentary phenotype
- abnormal intestinal transit time
- whole-gut transit time (WGTT) is significantly prolonged compared to controls starting at 3 months through 12 months of age; (MGI Ref ID J:156741)
- abnormal large intestinal transit time
- motility of distal colon is reduced in males compared to controls at 6 and 12 months (MGI Ref ID J:156741)
- amount of stool passed/unit time and stool water content are unchanged at 3 months of age but by 6 months these parameters are reduced to comparable degrees (MGI Ref ID J:156741)
- at 12 months of age, changes in stool production and water content are even more marked (MGI Ref ID J:156741)
- reduction in stool wet weigh results from a reduction in water content and reduction in the dry mass of stool output (MGI Ref ID J:156741)
- behavior/neurological phenotype
- *normal* behavior/neurological phenotype
- mice show no motor abnormalities; rotarod latencies and distances traveled in open field tests are similar to controls at 6 and 12 months (MGI Ref ID J:156741)
View Research Applications
Research Applications
This mouse can be used to support research in many areas including:
Internal/Organ Research
Gastrointestinal Defects
Neurobiology Research
Ataxia (Movement) Defects
Parkinson's Disease
synuclein mutants
Research Tools
Neurobiology Research
| Allele Symbol | Sncatm1Nbm | ||
|---|---|---|---|
| Allele Name | targeted mutation 1, Robert L Nussbaum | ||
| Allele Type | Targeted (knock-out) | ||
| Common Name(s) | Scna-; Snca-; | ||
| Strain of Origin | 129S6/SvEvTac | ||
| Gene Symbol and Name | Snca, synuclein, alpha | ||
| Chromosome | 6 | ||
| Gene Common Name(s) | NACP; PARK1; PARK4; PD1; alpha-synuclein; alphaSYN; | ||
| Molecular Note | Exons 4 and 5 were replaced with a neomycin selection cassette inserted by homologous recombination. While the separation of Western blot results by 2D-PAGE showed various isoforms in total brain extract obtained from wild-type mice, protein was undetected in samples obtained from homozygous mutant mice. [MGI Ref ID J:79784] | ||
| Allele Symbol | Tg(SNCA*A30P)1Nbm | ||
| Allele Name | transgene insertion 1, Robert L Nussbaum | ||
| Allele Type | Transgenic (random, expressed) | ||
| Common Name(s) | PAC-Tg(SCNAA30P) line 1; | ||
| Strain of Origin | FVB/N | ||
| Expressed Gene | SNCA, synuclein, alpha (non A4 component of amyloid precursor), human | ||
| Promoter | SNCA, synuclein, alpha (non A4 component of amyloid precursor), human | ||
| Molecular Note | To generate the PAC-Tg(SNCAA30P) transgene, the 146 kb RPCI-1 human male P1 artificial chromosome (PAC) clone 27M07, containing the entire human SNCA (synuclein, alpha (non A4 component of amyloid precursor)) gene and 34 kb of its upstream region, was modified to have the A30P human mutation associated with autosomal dominant Parkinson's disease. This transgene was microinjected into the pronuclei of fertilized FVB/N ova. The transgene inserted on the X chromosome. [MGI Ref ID J:154971] [MGI Ref ID J:156741] | ||
| Allele Symbol | Tg(SNCA*A30P)2Nbm | ||
| Allele Name | transgene insertion 2, Robert L Nussbaum | ||
| Allele Type | Transgenic (random, expressed) | ||
| Common Name(s) | PAC-Tg(SCNAA30P) line 2; | ||
| Strain of Origin | FVB/N | ||
| Expressed Gene | SNCA, synuclein, alpha (non A4 component of amyloid precursor), human | ||
| Promoter | SNCA, synuclein, alpha (non A4 component of amyloid precursor), human | ||
| Molecular Note | To generate the PAC-Tg(SNCAA30P) transgene, the 146 kb RPCI-1 human male P1 artificial chromosome (PAC) clone 27M07, containing the entire human SNCA (synuclein, alpha (non A4 component of amyloid precursor)) gene and 34 kb of its upstream region, was modified to have the A30P human mutation associated with autosomal dominant Parkinson's disease. This transgene was microinjected into the pronuclei of fertilized FVB/N ova. The transgene inserted onto a somatic chromosome. [MGI Ref ID J:154971] [MGI Ref ID J:156741] | ||
Genotyping Protocols
Tg(Prnp-SNCA*A53T)83Vle, QPCR
Tg(SNCA), Standard PCR
Note that the Tg(SNCA*30P)1Nbm transgene inserted on the X chromosome.
Helpful Links
Genotyping resources and troubleshooting
Cabin DE; Shimazu K; Murphy D; Cole NB; Gottschalk W; McIlwain KL; Orrison B; Chen A; Ellis CE; Paylor R; Lu B; Nussbaum RL. 2002. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci 22(20):8797-807. [PubMed: 12388586] [MGI Ref ID J:79784]
Kuo YM; Li Z; Jiao Y; Gaborit N; Pani AK; Orrison BM; Bruneau BG; Giasson BI; Smeyne RJ; Gershon MD; Nussbaum RL. 2010. Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated {alpha}-synuclein gene mutations precede central nervous system changes. Hum Mol Genet :. [PubMed: 20106867] [MGI Ref ID J:156741]
Sncatm1Nbm relatedTg(SNCA*A30P)1Nbm relatedAustin SA; Floden AM; Murphy EJ; Combs CK. 2006. Alpha-synuclein expression modulates microglial activation phenotype. J Neurosci 26(41):10558-63. [PubMed: 17035541] [MGI Ref ID J:113229]
Barcelo-Coblijn G; Golovko MY; Weinhofer I; Berger J; Murphy EJ. 2007. Brain neutral lipids mass is increased in alpha-synuclein gene-ablated mice. J Neurochem 101(1):132-41. [PubMed: 17250686] [MGI Ref ID J:122525]
Cabin DE; Gispert-Sanchez S; Murphy D; Auburger G; Myers RR; Nussbaum RL. 2005. Exacerbated synucleinopathy in mice expressing A53T SNCA on a Snca null background. Neurobiol Aging 26(1):25-35. [PubMed: 15585343] [MGI Ref ID J:124976]
Ekstrand MI; Terzioglu M; Galter D; Zhu S; Hofstetter C; Lindqvist E; Thams S; Bergstrand A; Hansson FS; Trifunovic A; Hoffer B; Cullheim S; Mohammed AH; Olson L; Larsson NG. 2007. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc Natl Acad Sci U S A 104(4):1325-30. [PubMed: 17227870] [MGI Ref ID J:119515]
Ellis CE; Murphy EJ; Mitchell DC; Golovko MY; Scaglia F; Barcelo-Coblijn GC; Nussbaum RL. 2005. Mitochondrial lipid abnormality and electron transport chain impairment in mice lacking alpha-synuclein. Mol Cell Biol 25(22):10190-201. [PubMed: 16260631] [MGI Ref ID J:102361]
Gispert S; Del Turco D; Garrett L; Chen A; Bernard DJ; Hamm-Clement J; Korf HW; Deller T; Braak H; Auburger G; Nussbaum RL. 2003. Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol Cell Neurosci 24(2):419-29. [PubMed: 14572463] [MGI Ref ID J:86222]
Golovko MY; Faergeman NJ; Cole NB; Castagnet PI; Nussbaum RL; Murphy EJ. 2005. Alpha-synuclein gene deletion decreases brain palmitate uptake and alters the palmitate metabolism in the absence of alpha-synuclein palmitate binding. Biochemistry 44(23):8251-9. [PubMed: 15938614] [MGI Ref ID J:99690]
Golovko MY; Rosenberger TA; Faergeman NJ; Feddersen S; Cole NB; Pribill I; Berger J; Nussbaum RL; Murphy EJ. 2006. Acyl-CoA synthetase activity links wild-type but not mutant alpha-synuclein to brain arachidonate metabolism. Biochemistry 45(22):6956-66. [PubMed: 16734431] [MGI Ref ID J:109641]
Kurz A; Double KL; Lastres-Becker I; Tozzi A; Tantucci M; Bockhart V; Bonin M; Garcia-Arencibia M; Nuber S; Schlaudraff F; Liss B; Fernandez-Ruiz J; Gerlach M; Wullner U; Luddens H; Calabresi P; Auburger G; Gispert S. 2010. A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice. PLoS One 5(7):e11464. [PubMed: 20628651] [MGI Ref ID J:163115]
Kurz A; Wohr M; Walter M; Bonin M; Auburger G; Gispert S; Schwarting RK. 2010. Alpha-synuclein deficiency affects brain Foxp1 expression and ultrasonic vocalization. Neuroscience 166(3):785-95. [PubMed: 20056137] [MGI Ref ID J:159729]
Steidinger TU; Standaert DG; Yacoubian TA. 2011. A neuroprotective role for angiogenin in models of Parkinson's disease. J Neurochem 116(3):334-41. [PubMed: 21091473] [MGI Ref ID J:170263]
Watson JB; Hatami A; David H; Masliah E; Roberts K; Evans CE; Levine MS. 2009. Alterations in corticostriatal synaptic plasticity in mice overexpressing human alpha-synuclein. Neuroscience 159(2):501-13. [PubMed: 19361478] [MGI Ref ID J:148932]
Westerlund M; Ran C; Borgkvist A; Sterky FH; Lindqvist E; Lundstromer K; Pernold K; Brene S; Kallunki P; Fisone G; Olson L; Galter D. 2008. Lrrk2 and alpha-synuclein are co-regulated in rodent striatum. Mol Cell Neurosci 39(4):586-91. [PubMed: 18790059] [MGI Ref ID J:142519]
Tg(SNCA*A30P)2Nbm relatedNussbaum RL. 2009. Generation of SNCA transgenes carrying A3OP mutations MGI Direct Data Submission :. [MGI Ref ID J:154971]
Nussbaum RL. 2009. Generation of SNCA transgenes carrying A3OP mutations MGI Direct Data Submission :. [MGI Ref ID J:154971]
Animal Health Reports
Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.Colony Maintenance
Breeding & Husbandry Because PAC-Tg(SNCAA30P) line 1 inserted on the X chromosome and line 2 inserted on a somatic chromosome, females homozygous for the Snca targeted mutation and homozygous for both Tg(SNCAA30P) transgenes (also called homozygous dbl-PAC-Tg(SNCAA30P);Snca-/- females) have four total insertions of the transgene. Males homozygous for the Snca targeted mutation, hemizygous for the X-linked Tg(SNCAA30P) line 1, and homozygous for the somatic inserted Tg(SNCAA30P) line 2 (also called homozygous dbl-PAC-Tg(SNCAA30P);Snca-/- males) have three total insertions of the transgene. When maintaining a live colony, females homozygous for the Snca targeted mutation and homozygous for both Tg(SNCAA30P) transgenes are bred with males homozygous for the Snca targeted mutation, hemizygous for the X-linked Tg(SNCAA30P) line 1, and homozygous for the somatic inserted Tg(SNCAA30P) line 2. The experimental control strain is Stock No. 010710.
| Pricing for USA, Canada and Mexico shipping destinations |
|
Cryopreserved Mice - Ready for Recovery
Animals Provided
Price (US dollars $) Cryorecovery* $2450.00 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
Standard Supply
Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.
Supply Notes
Cryorecovery - Standard.
Progeny testing is not required.
The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 11 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.Cryorecovery to establish a Dedicated Supply for greater quantities of mice
Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).
| Pricing for International shipping destinations |
|
Cryopreserved Mice - Ready for Recovery
Animals Provided
Price (US dollars $) Cryorecovery* $3185.00 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
Standard Supply
Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.
Supply Notes
Cryorecovery - Standard.
Progeny testing is not required.
The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 11 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.Cryorecovery to establish a Dedicated Supply for greater quantities of mice
Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).
|
|
Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.
| Control | ||
|---|---|---|
| None Available | ||
| Considerations for Choosing Controls | ||
| Control Pricing Information for Genetically Engineered Mutant Strains. | ||
For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.